Company intelligence / Profile preview

Cancer Check Labs

Dallas, Texas, United Statescancerchecklabs.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cancer Check Labs has developed a proprietary blood test that can detect more than 200 types and sub-types of solid tumor cancers by isolating whole, intact circulating tumor cells from a standard blood draw. The test provides results as early as Stage 0 cancer, with each result reviewed by a board-certified pathologist. The company claims this approach offers earlier and more reliable detection compared to ctDNA or AI-based methods. Initial clinical findings demonstrate robust capture of CTCs in early-stage patients, supporting the potential for improved survival through earlier intervention.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy
Industry: Pathology

Partnerships

Partnership with clinics in the UK for international expansion

Beyond the preview

Go deeper on Cancer Check Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancer Check Labs.

Explore the full profile